Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 편욱범 | * |
dc.date.accessioned | 2016-08-29T12:08:44Z | - |
dc.date.available | 2016-08-29T12:08:44Z | - |
dc.date.issued | 2016 | * |
dc.identifier.issn | 0167-5273 | * |
dc.identifier.other | OAK-16116 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/230918 | - |
dc.description.abstract | Background/objectives: The effect of aspirin and clopidogrel in a fixed-dose combination (FDC) on platelet function was compared with separate formulations in patients that had undergone percutaneous coronary intervention (PCI) with drug-eluting stent (DES). Methods: This was a phase IV, prospective, multicenter, single-arm, non-inferiority study. Patients that had taken aspirin 100 mg and clopidogrel 75 mg once daily as separate formulations for > 6 months after PCI with DES were enrolled, and then switched to an aspirin/clopidogrel FDC once-daily for 4 weeks. Platelet reactivity was determined using the VerifyNow® P2Y12 assay at baseline (immediately prior to switching) and 4 weeks later. Results: A total of 648 patients (the full-analysis population; age, 63.6 ± 9.0 years; male, 76.5%) finished the study, and 565 (the per-protocol population) completed without protocol violations. In the per-protocol population, the % inhibitions of P2Y12 and ARU were not significantly different between baseline and after 4 weeks of FDC treatment (29.2 ± 20.0% to 29.0 ± 19.9%, P = 0.708; 445.1 ± 69.2 to 446.2 ± 63.0, P = 0.799, respectively) and the difference in P2Y12 inhibition observed did not exceed the predetermined limit of non-inferiority (95% CI, - 0.9 to 1.3). In the full-analysis population, the % inhibitions of P2Y12, PRU, and ARU were not significantly changed after 4 weeks of FDC treatment. Conclusions This study demonstrates that the efficacy of platelet inhibition by an aspirin/clopidogrel FDC was not inferior to that of separate aspirin and clopidogrel formulations in patients that had undergone PCI with DES. © 2015, Elsevier Ireland Ltd. All rights reserved. | * |
dc.language | English | * |
dc.publisher | Elsevier Ireland Ltd | * |
dc.subject | Aspirin | * |
dc.subject | Clopidogrel | * |
dc.subject | Fixed-dose combination | * |
dc.subject | Platelet function | * |
dc.title | Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial | * |
dc.type | Article | * |
dc.relation.volume | 202 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 331 | * |
dc.relation.lastpage | 335 | * |
dc.relation.journaltitle | International Journal of Cardiology | * |
dc.identifier.doi | 10.1016/j.ijcard.2015.09.024 | * |
dc.identifier.wosid | WOS:000366161500080 | * |
dc.identifier.scopusid | 2-s2.0-84960155503 | * |
dc.author.google | Oh P.C. | * |
dc.author.google | Ahn T. | * |
dc.author.google | Kim D.W. | * |
dc.author.google | Hong B.-K. | * |
dc.author.google | Kim D.-S. | * |
dc.author.google | Kwan J. | * |
dc.author.google | Choi C.U. | * |
dc.author.google | Yang Y.-M. | * |
dc.author.google | Bae J.H. | * |
dc.author.google | Jung K.T. | * |
dc.author.google | Choi W.G. | * |
dc.author.google | Jeon D.W. | * |
dc.author.google | Cho D.K. | * |
dc.author.google | Pyun W.B. | * |
dc.author.google | Cha K.S. | * |
dc.author.google | Cha T.-J. | * |
dc.author.google | Chun K.J. | * |
dc.author.google | Kim Y.D. | * |
dc.author.google | Kim B.S. | * |
dc.author.google | Kim D.-I. | * |
dc.author.google | Kim T.I. | * |
dc.contributor.scopusid | 편욱범(6508352922) | * |
dc.date.modifydate | 20240123092816 | * |